Japan is the world’s third-largest pharmaceutical market and one of Asia’s most sophisticated regulatory environments. For manufacturers of cosmetics, over-the-counter health products, and topical preparations, Japan presents a unique challenge: a three-tier classification system that places many products in a category that does not exist in most other regulatory frameworks. That category is the quasi-drug. Understanding the Japan quasi drug pathway is not optional for companies seeking meaningful market presence in Japan.
Misclassifying a product or failing to appreciate the distinction between a quasi-drug and a cosmetic or a pharmaceutical results in wrong regulatory strategy, wrong submission pathway, and costly delays. This blog provides a structured explanation of Japan’s quasi-drug classification and the practical steps required to register these products with the PMDA and MHLW.
Regulatory Authorities of Japan - PMDA and MHLW
Japan’s pharmaceutical regulatory system operates through two bodies. The Ministry of Health, Labour and Welfare (MHLW) is the governmental authority that grants marketing authorizations and sets policy. The Pharmaceuticals and Medical Devices Agency (PMDA) is the independent agency that conducts scientific reviews, on-site inspections, and adverse effect assessments on behalf of MHLW. Applications submitted to PMDA are forwarded to MHLW for the final decision.
Both bodies operate under the Pharmaceutical and Medical Devices Act (PMD Act), also known as the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics. This law governs classification, licensing, registration, and post-market surveillance for all health-related products in Japan.
Japan's Three-Category Classification
General Cosmetics
General cosmetics are products applied to the human body for the purpose of cleaning, beautifying, or maintaining appearance by mild actions. They do not require regulatory application for market approval but must comply with the Cosmetics Product Standards issued by MHLW. Products in this category may only use ingredients from MHLW’s positive list of approved cosmetic ingredients. If a product contains an ingredient outside the positive list, it likely falls outside the cosmetics category.
Quasi-Drugs
Quasi-drugs occupy the regulatory space between cosmetics and pharmaceuticals. They are products with active ingredients that have mild pharmacological effects intended to achieve a specific functional outcome. Examples include medicated shampoos with anti-dandruff agents, skin-whitening products containing specific active ingredients such as arbutin or vitamin C derivatives, hair growth stimulants, and OTC topical preparations for acne or oral hygiene.
As of 2024, Japan has strengthened scrutiny on skin-lightening agents and anti-hair loss formulations due to emerging safety concerns, which has affected both approval timelines and post-market monitoring expectations for products in these sub-categories. Japan’s quasi-drug segment was valued at over USD 10 billion in 2024, driven by aging population needs and personal hygiene awareness.
Pharmaceuticals
Pharmaceutical products in Japan require the most rigorous approval process, including clinical evidence of efficacy and safety. OTC drugs that make therapeutic claims beyond mild cosmetic or hygiene functions are classified as pharmaceuticals, not quasi-drugs. The boundary is not always obvious, and PMDA consultations are often the most efficient way to resolve classification uncertainty.
Step-by-Step Process of Japan's Quasi Drug Pathway
Step 1: Business License for Marketing Authorization
Before any product can be marketed in Japan, the sponsor must hold a Marketing Authorization Holder (MAH) license. Foreign manufacturers who wish to import quasi-drugs must either establish a Japanese legal entity or appoint an accredited Japanese MAH as their representative. The MAH owns the marketing authorization and bears regulatory responsibility for the product.
Foreign manufacturers wishing to manufacture quasi-drugs outside Japan and import them must obtain accreditation as an Accredited Foreign Manufacturer. The application requires submission to the Director-General of the Regional Bureau of Health and Welfare and involves a PMDA examination of the manufacturing establishment. Required documents include facility blueprints, a description of the manufacturing process, a list of products to be imported, and a CV of the responsible person.
Step 2: Prepare the Product Dossier
The quasi-drug dossier is submitted to PMDA and includes: the list of active and inactive ingredients with safety and quality justification, formulation details and manufacturing process description, clinical or non-clinical data demonstrating the claimed functional effect, packaging and labeling design, and GQP (Good Quality Practice) and GVP (Good Vigilance Practice) compliance documentation.
For products using active ingredients already on the MHLW’s approved notification list, the approval process is streamlined through a notification-based pathway. For products using new active ingredients or making novel claims, a full approval application is required, and clinical studies may be necessary to support the efficacy claim.
Step 3: Labeling and Claims Compliance
Claims for quasi-drugs are strictly regulated. Only claims that correspond to the approved indication and active ingredient are permitted. Japan’s labeling law requires all labels to be in Japanese. Claims must not imply pharmaceutical efficacy. The distinction between a cosmetic claim such as ‘improves skin tone’ and a quasi-drug claim such as ‘suppresses melanin production to prevent spots and freckles’ is intentional and must be maintained.
Step 4: GMP and GQP Compliance
Manufacturing facilities for quasi-drugs must comply with GMP standards as defined by MHLW. For foreign manufacturing sites, PMDA conducts on-site GMP conformity assessments or document-based assessments. The site must demonstrate that manufacturing processes, quality controls, and batch release procedures meet Japanese standards. GQP compliance is required at the MAH level and governs how the MAH oversees manufacturing quality.
Step 5: Post-Market Obligations
Post-market obligations for quasi-drugs include GVP compliance, which requires systems for collecting and reporting adverse events, conducting post-market surveillance, and maintaining product complaint records. Japan’s adverse event reporting requirements are specific and require designated timelines for reporting serious events to MHLW.
Key Differences from Other Markets
A product that is a cosmetic in the EU or US may require quasi-drug registration in Japan if its active ingredient or intended claim fits within the MHLW’s quasi-drug categories. This category mismatch is one of the most common sources of regulatory delay for foreign companies entering Japan. Manufacturers should conduct a Japan-specific regulatory assessment, including a comparison of the product’s active ingredients against MHLW’s approved quasi-drug ingredient lists, before assuming that their existing regulatory category is transferable.
OTC Drug Registration in PMDA
OTC drugs in Japan fall within the pharmaceutical classification and require approval through the PMDA standard pathway. For products previously approved in ICH countries, bridging data is typically required to support Japanese registration. The eCTD format is mandatory, and PMDA will require eCTD v4.0 from April 2026.
The PMDA conducts a five-point evaluation for new OTC drug applications: reliability of studies, evidence of superiority over placebo, clinical significance of results, acceptability of risk relative to benefit, and capacity for stable supply with consistent quality assurance.
Practical Advice for Foreign Manufacturers
- Engage a Japan-based regulatory consultant or licensed MAH partner before initiating any product development for the Japanese market.
- Conduct a classification review using Japan’s PMD Act criteria rather than assuming EU or US classification applies.
- Submit a pre-consultation request to PMDA to confirm classification and discuss the expected dossier content before incurring significant development costs.
- Build the GQP and GVP systems at the MAH level before the product approval is granted, as these must be in place at launch.
Conclusion
Japan’s quasi-drug category is not a regulatory shortcut. It is a distinct legal classification with its own submission requirements, approval standards, and post-market obligations. For manufacturers of medicated cosmetics, functional OTC products, and topical health preparations, understanding this framework is the precondition for any successful Japan market entry strategy.
Read more from our experts here: Pharmaceutical Registration in Saudi Arabia: A Complete SFDA Roadmap for 2026